Treatment of Chronic Anger and Aggression Following Military-Related Betrayal

NCT ID: NCT06609330

Last Updated: 2025-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-17

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if a treatment designed to deal with anger and aggression from a past betrayal will work. The study will be done on active duty military service members and veterans aged 18 or older. The main questions it aims to answer are:

* Will participants be satisfied with the treatment, and is the treatment feasible to do in a military outpatient setting
* Will the treatment help with anger and aggression issues.

Researchers will compare differences in groups that have different wait times (2-, 3-, or 4-weeks).

Participants will complete surveys before, during and after the treatment. The treatment will be 14 modules given twice a week. About 1 month after treatment ends, surveys will be taken again.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will undergo the study procedures described below. The preferred method of assessment and treatment is face-to-face in the STRONG STAR offices at Fort Cavazos. However, there may be circumstances when participants can complete the treatment through telebehavioral health (i.e., by phone or using a HIPAA-compliant video calling platform like Zoom). Decisions will be made on a case-by-case basis as issues arise for individuals (e.g., childcare) and in discussion with the treatment team. If participants do not have internet access they may need to complete assessments in person at the STRONG STAR office or by phone.

* During the wait time:

* Complete a 5-10 minute assessment twice per week (Monday/Thursday or Tuesday/Friday) to assess level of anger, aggression, and interactions with others since last assessment.
* The assigned therapist will call participants once a week for a 10-minute, check-in.
* At the end of participants' assigned wait time, they will complete an assessment of level of anger, aggression, interactions with others, mental, and physical health.
* During treatment:

* Begin treatment within 1 week of last wait time assessment.
* Participate in 7-24 (average 14) one-hour bi-weekly (Monday/Thursday or Tuesday/Friday) CART sessions.
* Prior to each session, participants will complete the same 5-10 minute assessment to assess level of anger, aggression, and interactions with others since last assessment.
* At the final treatment session, participants will be scheduled to complete a 1-month follow-up assessment.
* For follow-up:

* Complete a 1-month follow up assessment between 4-8 weeks after the final treatment session.
* Participants will be sent a link to complete the follow-up assessment.
* Complete the same questionnaires completed at pre-treatment plus an exit interview and a brief satisfaction survey.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anger Problems Aggression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Upon enrollment into the study, participants will begin with a minimal contact wait condition followed by randomization to different wait times (2-, 3-, or 4-weeks)
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2-week wait time group

This group is randomized to a 2-week wait time prior to treatment with CART

Group Type EXPERIMENTAL

Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)

Intervention Type BEHAVIORAL

Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.

3-week wait time group

This group is randomized to a 3-week wait time prior to treatment with CART

Group Type EXPERIMENTAL

Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)

Intervention Type BEHAVIORAL

Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.

4-week wait time group

This group is randomized to a 4-week wait time prior to treatment with CART

Group Type EXPERIMENTAL

Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)

Intervention Type BEHAVIORAL

Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)

Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CART

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult active duty military service members and veterans aged 18 or older.
* Endorses a history of military-related betrayal (on the Modified Moral Injury Questionnaire)
* Endorses problematic anger in the past month (as evidenced by a score of 12 or above on the Dimensions of Anger Reactions; DAR-5)
* Engaged in at least 1 self-reported act of aggression in the past 1 month (on the Overt Aggression Scale-Modified; OAS-M)

Exclusion Criteria

* Participated in an anger management or trauma-focused intervention within the past 3 months as assessed by self-report.
* Acute suicidality requiring immediate intervention, such as hospitalization as assessed by the Depressive Symptoms Index-Suicidality Subscale (DSI-SS) combined with follow up clinical interview for elevated scores.
* Is currently homicidal with plans and intent to hurt a specific person and requiring immediate intervention as measured by self-report and follow-up with clinician if screened positive.
* Moderate to severe brain injury as measured by inability to comprehend the informed consent document or baseline assessments.
* Has severe alcohol consumption patterns as evidenced by a score of 19 or above on the Alcohol Use Disorders Identification Test (AUDIT).
* Experiencing active psychosis or mania as measured by the Prodromal Questionnaire-Brief Version and the Mood Disorders Questionnaire.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

United States Department of Defense

FED

Sponsor Role collaborator

The University of Texas Health Science Center at San Antonio

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vanessa Jacoby

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vanessa Jacoby, PhD

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Alan Peterson, PhD

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Carl R. Darnall Army Medical Center (CRDAMC) at Fort Cavazos

Fort Cavazos, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Vanessa Jacoby, PhD

Role: CONTACT

(254) 289-3468

Alan Peterson, PhD

Role: CONTACT

(210) 562-6700

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Vanessa Jacoby, PhD

Role: primary

254-289-3468

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

W81XWH-22-2-0085

Identifier Type: OTHER

Identifier Source: secondary_id

20230329HU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment Seeking Study
NCT05077514 COMPLETED NA
Treatment of Post-TBI Depression
NCT00211835 COMPLETED NA
Behavioral Activation With Depressed Adolescents
NCT01137149 UNKNOWN PHASE1/PHASE2